Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27518244 | 1.00 | IDO1 (0.39) | IDO1PLAUHTR2ARETHTR2C | |
| SCHEMBL7113339 | 0.79 | DRD3 (0.41) | IDO1PLAUHTR2AOPRD1DPP4 | |
| Hydrochloric Acid SCHEMBL7112616 | 0.78 | IDO1 (0.41) | IDO1PLAUHTR2AANPEPOPRD1 | |
| SCHEMBL24890476 | 0.76 | IDO1 (0.43) | IDO1PLAUHTR2AANPEPDPP4 | |
| SCHEMBL7092681 | 0.75 | IDO1 (0.46) | IDO1PLAUHTR2ARETANPEP | |
| SCHEMBL28785332 | 0.72 | OPRD1 (0.40) | IDO1OPRD1DPP4DPP8DPP9 | |
| SCHEMBL12804575 | 0.71 | HTR2A (0.50) | IDO1PLAUHTR2A | |
| SCHEMBL12936160 | 0.71 | HTR2A (0.50) | IDO1PLAUHTR2A | |
| SCHEMBL10290580 | 0.71 | TACR1 (0.50) | IDO1HTR2ARETHTR2CHRH1 | |
| SCHEMBL4666509 | 0.70 | IDO1 (0.41) | IDO1PLAUANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034513-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-7842718-B2 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7691884-B2 | Heterocyclic sulfonamide inhibitors of β amyloid production | WYETH (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100022594-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2010-01-28 | — | — | US | disclosed |
| CN-1263750-C | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH CORP (US) | 2006-07-12 | — | — | CN | disclosed |
| CN-1800176-A | Heterocyclic sulfonamide inhibitors of beta amyloid production | ARQULE (US) | 2006-07-12 | — | — | CN | disclosed |
| EP-1341779-B1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050196813-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH (US) | 2005-09-08 | — | — | US | disclosed |
| US-6878742-B2 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH (US) | 2005-04-12 | — | — | US | disclosed |
| CN-1503790-A | Heterocyclic sulfonamide inhibitors of beta amyloid production | — | 2004-06-09 | — | — | CN | disclosed |
| US-20030229127-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH | 2003-12-11 | — | — | US | disclosed |
| EP-1341779-A2 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | Wyeth (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6610734-B2 | For therapy of Alzheimer's Disease and Down's syndrome | WYETH | 2003-08-26 | — | — | US | disclosed |
| US-20020183361-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | ARQULE | 2002-12-05 | — | — | US | disclosed |
| WO-2002057252-A2 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229127-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | APP, BACE1, PSEN1 | IDO1 3199/4885PLAU 3906/4885HTR2A 654/4885 |
| US-20100022594-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | APP, BACE1, PSEN1 | IDO1 3277/4885PLAU 4036/4885HTR2A 391/4885 |
| US-20110034513-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production | APP, BACE1, PSEN1 | IDO1 3277/4885PLAU 4036/4885HTR2A 391/4885 |
| US-20020183361-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | APP, BACE1, PSEN1 | IDO1 3199/4885PLAU 3906/4885HTR2A 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.